This symposium will review the emerging evidence in the field of bronchiectasis including new data from randomized controlled trials of inhaled antibiotics, cutting edge science around endotyping, and the application of personalized medicine as well as evidence for emerging therapies targeting inflammation.
• Describe new findings about the epidemiology and unmet need in patients with bronchiectasis
• Improve the treatment of bronchiectasis patients by better applying the evidence for long term inhaled and oral antibiotics in clinical practice
• Improve the treatment of bronchiectasis patients by better applying the evidence for mucus clearance treatments including airway clearance/physiotherapy and mucus targeting treatments
John Torrence
Emily Henkle, PhD, MPH
Ashwin Basavaraj, MD, FCCP, ATSF
Timothy Aksamit, MD
James Chalmers, MD, PhD
A Patient's Perspective
Epidemiological Approaches to Investigating Treatment Effects and Unmet Need
New Data for Airway Clearance and Mucoactive Approaches in Bronchiectasis
The Role of Long Term Antibiotic Treatments in BronchiectasisNeutrophils, Eosinophils and Endotyping Bronchiectasis